AviadoBio appoints David Cooper as CMO

2 August 2022

Pre-clinical stage gene therapy company AviadoBio has announced the appointment of David Cooper as chief medical officer (CMO).

Dr Cooper worked previously as vice president, clinical development for Dutch company uniQure (Nasdaq: QURE), leading the translation of pre-clinical gene therapy assets to the clinic and executing on multiple clinical programs up to Phase III. This included the pioneering first human dose studies in the USA and European Union for intraparenchymal gene therapy for early-stage Huntington’s disease.

"I have no doubt he will make a tremendous impact as we advance our gene therapies into the clinic"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK